Procept Biorobotics

PRCT

Market cap $1.27B

MILWAUKEE, Feb. 26, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against PROCEPT BioRobotics (NASDAQ: PRCT). The investigation results from inaccurate statements PROCEPT BioRobotics may have made regarding its financial statements, business operations and prospects.

PROCEPT BioRobotics Corporation (PRCT) Q4 2025 Earnings Call Transcript

Procept Biorobotics stock crashed Thursday on a hard-to-stomach update that included light fourth-quarter sales and a 2026 guidance cut.

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today hosted its 2026 Investor Day event in New York to detail the Company's market opportunity, long-term strategy and growth goals, and 2026 - 2027 financial guidance.

PROCEPT BioRobotics Corp. (NASDAQ: PRCT) shares are down during Thursday's premarket session following the company's recent financial results and updates on its revenue guidance.

PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.35 per share a year ago.

SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended December 31, 2025.

SAN JOSE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that it has updated the timing of its previously announced fourth quarter 2025 earnings conference call and Investor Day due to significant travel disruptions caused by inclement weather.

SAN JOSE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that members of management will present at two upcoming investor conferences in March.

Chicago Capital sold 377,850 shares of PRCT in the fourth quarter; the estimated transaction value was $12.53 million based on quarterly average pricing. Meanwhile, the quarter-end position value declined by $18.52 million, reflecting both trading and stock price movement.